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Ureaplasma urealyticum and Ureaplasma parvum are pathogens involved in urogenital tract and intrauterine infections and
also in systemic diseases in newborns and immunosuppressed patients. There is limited information on the antimicrobial sus-
ceptibility and clonality of these species. In this study, we report the susceptibility of 250 contemporary isolates ofUreaplasma
(202 U. parvum and 48 U. urealyticum isolates) recovered at Mayo Clinic, Rochester, MN. MICs of doxycycline, azithromycin,
ciprofloxacin, tetracycline, erythromycin, and levofloxacin were determined by broth microdilution, withMICS of the last three
interpreted according to CLSI guidelines. Levofloxacin resistance was found in 6.4% and 5.2% of U. parvum and U. urealyticum
isolates, respectively, while 27.2% and 68.8% of isolates, respectively, showed ciprofloxacinMICs of>4g/ml. The resistance
mechanism of levofloxacin-resistant isolates was due to mutations in parC, with the Ser83Leu substitution being most frequent,
followed by Glu87Lys. No macrolide resistance was found among the 250 isolates studied; a singleU. parvum isolate was tetracy-
cline resistant. tet(M) was found in 10U. parvum isolates, including the single tetracycline-resistant isolate, as well as in 9 iso-
lates which had low tetracycline and doxycycline MICs. Multilocus sequence typing (MLST) performed on a selection of 46 iso-
lates showed high diversity within the clinicalUreaplasma isolates studied, regardless of antimicrobial susceptibility. The
present work extends previous knowledge regarding susceptibility to antimicrobial agents, resistance mechanisms, and clonality
ofUreaplasma species in the United States.
Ureaplasmas are bacteria belonging to the class Mollicutes.They are small, self-replicating organisms, capable of cell-free
existence (1). Their small genomes and limited biosynthetic abil-
ities are responsible for many of their biological characteristics
and requirements for complex growth media for cultivation in
vitro (1). Ureaplasmas of medical importance are subclassified
into two distinct species, Ureaplasma parvum and Ureaplasma
urealyticum; the former is more frequently recovered than the
latter (1).
U. urealyticum and U. parvum are part of the human microbi-
ota but are also involved in urogenital tract infection and associ-
ated with adverse pregnancy outcomes and bacteremia alongside
complications such as bronchopulmonary dysplasia and menin-
gitis in newborns (1–5). Recently, Ureaplasma species have been
associated with fatal hyperammonemia among lung transplant
patients (6). Furthermore, some authors suggest thatUreaplasma
infections may be involved in other unexplained hyperammone-
mia syndromes (7).
Antimicrobial options for treating Ureaplasma infections are
limited. Since this genus lacks peptidoglycan, ureaplasmas are not
affected by -lactams or other antimicrobial agents acting on this
target. Moreover, they are not susceptible to sulfonamides or tri-
methoprim since they do not synthesize folic acid. However,
members of this genus are frequently susceptible to antimicrobials
that interfere with protein synthesis (macrolides and tetracy-
clines) and to DNA replication inhibitors (fluoroquinolones) (1,
8). Some reports of antimicrobial resistance in ureaplasmas have
been published. Resistance to fluoroquinolones has been attrib-
uted to mutations in gyrA, gyrB, parC, and parE, macrolide resis-
tance has been attributed tomutations in the 23S rRNA subunit or
in the ribosomal protein L4 or L22 gene, and tetracycline resis-
tance has been attributed to the presence of tet(M) (9–14).
Reports on the antimicrobial susceptibility of Ureaplasma are
limited, especially reports separated by species.Moreover, because
the multilocus sequence typing (MLST) scheme for this species
has been recently developed, there are only a few studies in which
the population distribution of this genus has been analyzed.
Therefore, the aimof this studywas to determine the susceptibility
and clonality of contemporary isolates of Ureaplasma from the
United States recovered at Mayo Clinic, Rochester, MN (includ-
ing isolates from Mayo Medical Laboratories patients).
(Part of this research was presented at ASM Microbe 2016,
Boston, MA, 16 to 20 June 2016.)
MATERIALS AND METHODS
Specimens and isolates.Over a 5-month period (October 2015 to Febru-
ary 2016), all patient specimens of any origin testing positive by PCR at
Mayo Clinic (Rochester, MN, USA) forU. parvum orU. urealyticum (15)
were cultured in SP4mediumwith urea (HardyDiagnostics, SantaMaria,
CA). A total of 250 clinical isolates (202U. parvum and 48U. urealyticum
isolates) were recovered and characterized. The source of the samples was
diverse and included urine (35.6%), vagina (31.2%), cervix (22.4%), se-
men (4.8%), bronchoalveolar lavage fluid (1.6%), urethra (1.2%), tra-
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cheal aspirates (1.2%), sputum (0.4%), vulva (0.4%), and other urogeni-
tal sources (1.2%).
Antimicrobial susceptibility testing.Doxycycline, azithromycin, cip-
rofloxacin, tetracycline, erythromycin, and levofloxacin (Sigma-Aldrich,
St. Louis, MO, USA) MICs were determined in duplicate by broth mi-
crodilution according to the Clinical and Laboratory Standards (CLSI)
guidelines (16), using a range of antimicrobial concentrations from 0.125
to 16g/ml in 10B broth (Remel, Lenexa, KS, USA). Only theMICs of the
last three antimicrobials were interpreted since there are no CLSI break-
points for the first three agents. U. urealyticum American Type Culture
Collection (ATCC) 33175 was used as a quality control (QC) strain in
each broth microdilution assay.
Identification of genes encoding tetracycline and fluoroquinolone
resistance. Bacterial DNA extraction from culture broth was performed
using a DNeasy blood and tissue kit (Qiagen, Valencia, CA). The tet(M)
gene was assessed by PCR, using previously described primers and cycling
conditions, in allUreaplasma isolates studied (11). For levofloxacin-resis-
tant strains, PCR of the quinolone resistance-determining regions
(QRDRs) of gyrA, gyrB, parC, and parE was performed as previously de-
scribed (9, 11). Both tet(M) and QRDR amplicons were purified using
ExoSAP-IT (USB Corporation, Cleveland, OH, USA) and bidirectionally
sequenced using an ABI 3730xl instrument (Applied Biosystems, Foster
City, CA). The gyrA, gyrB, parC, and parE sequences were analyzed using
CloneManager software (Sci-Ed Software, Cary, NC) and compared with
those of the reference strainsU. parvumATCC700970 andU. urealyticum
ATCC 33699 (GenBank accession numbers AF222894 and CP001184,
respectively) (9–11).
MLST.Multilocus sequence typing (MLST) was performed according
to the original scheme using primers targeting four housekeeping genes,
ftsH, rpl22, valS, and thrS (17), on 46 isolates (30 U. parvum and 16 U.
urealyticum isolates), including all levofloxacin-resistant isolates, all
tet(M)-positive isolates, and a group of susceptible isolates representative
of the different study periods and specimen sources. The eBURST pack-
age, version 3 (http://eburst.mlst.net/), was used based on allelic profiles
with 1,000 resamplings for bootstrapping to establish clonality and deter-
mine potential relationships between isolates.
Nucleotide sequence accession numbers. The following five new
MLST locus alleles were deposited in the GenBank database under the
indicated accession numbers: one for ftsH (KU710257), one for rpl22
(KU710255), two for valS (KU726275 and KU710256), and one for thrS
(KU710258).
RESULTS
Prevalence of resistance inUreaplasma by species.Of the 202U.
parvum and 48 U. urealyticum isolates tested, levofloxacin resis-
tance (MIC of 2 g/ml) was found in 6.4% and 5.2%, respec-
tively. All isolates had levofloxacin MICs at least one dilution
lower than the ciprofloxacin MICs. Although there are no CLSI
breakpoints for ciprofloxacin, 27.2% ofU. parvum and the 68.8%
of U. urealyticum isolates showed MICs of4 g/ml (the break-
point for levofloxacin and moxifloxacin). All U. urealyticum iso-
lates and all but one U. parvum isolate were susceptible to tetracy-
cline (MICs of2g/ml) and displayed equal or lower doxycycline
MICs. Coresistance to levofloxacin was observed in the single tetra-
cycline-resistant U. parvum isolate. All Ureaplasma isolates were
susceptible to erythromycin and had equal or lower azithromycin
MICs. Detailed results of MIC distributions, MIC50 and MIC90
values, and percentages of susceptibility by species ofUreaplasma
are shown in Table 1.
Molecular characterization of antimicrobial resistance. Se-
quence comparison between the QRDRs of reference strains and
the QRDRs of study levofloxacin-resistant isolates revealed no
mutations in gyrA, gyrB, or parE in any isolate; however, previ-
ously described parC quinolone resistance-associated mutations
were found. The most frequent mutation detected was Ser83Leu,
which was present in 12 (92.1%) and 1 (50%) of the levofloxacin-
resistant U. parvum and U. urealyticum isolates, respectively. The
remaining levofloxacin-resistant U. parvum isolate harbored a
Glu87Lys mutation, while no QRDR mutations were found in a
single levofloxacin-resistant U. urealyticum isolate. Three levo-
floxacin-susceptible isolates (two U. urealyticum isolates and one
U. parvum isolate) which showed ciprofloxacin MICs of 4
g/ml were also amplified and sequenced, with no mutations
found.
Screening of the tet(M) determinant, which is associated with
tetracycline resistance, was carried out, and 10 (4.9%) of the U.
parvum isolates were positive, while no U. urealyticum isolates
harbored this gene. Interestingly, the 10 positive isolates included
TABLE 1MIC distribution of Ureaplasma isolates separated by species
Species and
antimicrobiala
No. (%) of isolates with the indicated MIC (g/ml)
MIC50
(g/ml)
MIC90
(g/ml)
%
susceptibleb0.125 0.25 0.5 1 2 4 8 16 16
U. parvum
(n 202)
LEV 14 (6.9) 64 (31.7) 85 (42.1) 23 (11.4) 3 (1.5) 8 (4) 4 (2) 1 (0.5) 0.5 1 93.6
CIP 4 (2) 9 (4.4) 38 (18.8) 96 (47.5) 35 (17.3) 7 (3.5) 12 (5.9) 1 (0.5) 2 4 NA
TET 161 (79.7) 29 (14.4) 8 (4) 3 (1.5) 1 (0.5) 0.125 0.25 99.5
DOX 194 (96) 7 (3.5) 1 (0.5) 0.125 0.125 NA
ERY 8 (4) 32 (15.8) 63 (31.2) 66 (32.7) 31 (15.3) 1 (0.5) 1 (0.5) 0.5 2 100
AZM 8 (4) 41 (20.3) 66 (32.7) 57 (28.2) 28 (3.9) 1 (0.5) 1 (0.5) 0.5 2 NA
U. urealyticum
(n 48)
LEV 8 (16.7) 15 (31.2) 17 (35.4) 6 (12.5) 2 (4.2) 1 2 95.8
CIP 1 (2.1) 14 (29.2) 23 (47.9) 8 (16.7) 2 (4.2) 4 8 NA
TET 17 (35.4) 19 (39.6) 9 (18.7) 3 (6.2) 0.25 0.5 100
DOX 48 (100) 0.125 0.125 NA
ERY 1 (2.1) 5 (10.4) 2 (4.2) 17 (35.4) 22 (45.8) 1 (2.1) 1 2 100
AZM 1 (2.1) 5 (10.4) 5 (10.4) 17 (35.4) 20 (41.7) 1 2 NA
a LEV, levofloxacin; CIP, ciprofloxacin; TET, tetracycline; DOX, doxycycline; ERY, erythromycin; AZM, azithromycin; n, number of isolates.
b NA, not applicable (no CLSI breakpoint).
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the single tetracycline-resistantU. parvum isolate, as well as 9 iso-
lates for which the tetracycline and doxycycline MICs were low.
Detailed results of the genes responsible for antimicrobial re-
sistance and theMICs for a selection of isolates are summarized in
Table 2.
MLST and clonality. MLST revealed 14 clones among the 30
U. parvum isolates tested. ST1 and ST56, which belong to the same
clonal complex (CC) and have three shared loci, were the most
frequent clones, with six and five isolates, respectively, in each.
Among the 16U. urealyticum isolates studied, seven profiles were
TABLE 2Microbiological features of representative Ureaplasma isolates of the study
Species and isolate no.
Specimen
sourcea
MIC (g/ml)b
tet(M)
QRDRc MLST
LEV CIP TET DOX ERY AZM gyrA gyrB parC parE ftsH rpl22 valS rprS STd
U. parvum
IDRL-10860 Urine 4 16 0.125 0.125 0.5 0.5  WT WT S83L WT 1 1 1 1 ST1
IDRL-10857 Vagina 4 16 0.5 0.25 2 2  WT WT S83L WT 35 1 1 1 ST95
IDRL-10940 Vagina 8 16 0.125 0.125 0.5 0.5  WT WT S83L WT 8 1 1 1 ST56
IDRL-10790 Urethra 4 16 0.125 0.125 0.5 0.5  WT WT S83L WT 8 1 1 1 ST56
IDRL-10904 Cervix 4 16 8 2 0.5 0.5  WT WT S83L WT 2 1 1 1 ST2
IDRL-11151 Cervix 4 16 0.125 0.125 0.5 0.5  WT WT S83L WT 1 1 1 1 ST1
IDRL-11156 Urine 4 16 0.125 0.125 2 1  WT WT S83L WT 8 1 1 1 ST56
IDRL-11160 Urine 16 16 0.125 0.125 1 0.5  WT WT S83L WT 2 1 22e 1 ST108f
IDRL-11170 Vagina 8 16 0.125 0.125 0.25 0.25  WT WT S83L WT 1 2 1 1 ST22
IDRL-11178 Vagina 4 16 0.125 0.125 0.5 0.5  WT WT S83L WT 1 1 1 1 ST1
IDRL-11211 Vagina 4 16 0.125 0.125 1 0.5  WT WT S83L WT 1 1 23e 1 ST109f
IDRL-11260 Vagina 8 16 0.125 0.125 2 2  WT WT S83L WT 1 12 1 1 ST103
IDRL-11232 Cervix 8 16 0.125 0.125 1 1  WT WT E87K WT 20 2 1 1 ST111f
IDRL-11141 Vagina 0.5 2 0.25 0.125 1 1  ND ND ND ND 2 2 1 2 ST105
IDRL-11142 Vagina 0.5 2 0.25 0.125 0.5 0.5  ND ND ND ND 2 2 1 1 ST4
IDRL-11149 Urine 0.5 2 0.25 0.125 1 1  ND ND ND ND 8 1 1 1 ST56
IDRL-11152 Cervix 0.5 2 0.25 0.125 0.5 0.5  ND ND ND ND 2 2 1 1 ST4
IDRL-11177 Urine 0.5 2 0.125 0.125 0.5 0.5  ND ND ND ND 8 1 1 1 ST56
IDRL-11179 Vagina 0.5 2 0.125 0.125 0.5 0.25  ND ND ND ND 2 1 1 2 ST38
IDRL-11252 Vagina 0.25 0.5 0.125 0.125 0.25 0.25  ND ND ND ND 2 14e 1 1 ST110f
IDRL-11268 Vagina 0.5 2 0.125 0.125 2 2  ND ND ND ND 2 2 1 1 ST4
IDRL-10852 Vagina 0.25 2 0.125 0.125 2 2  ND ND ND ND 2 2 1 1 ST4
IDRL-10835 Cervix 2 8 0.125 0.125 0.5 0.5  WT WT WT WT 1 1 1 1 ST1
IDRL-10774 BAL 0.25 2 0.125 0.125 0.5 0.5  ND ND ND ND 1 2 1 1 ST22
IDRL-10874 Vagina 0.5 2 0.125 0.125 0.5 0.25  ND ND ND ND 1 1 1 1 ST1
IDRL-10923 Cervix 0.25 1 0.125 0.125 0.25 0.25  ND ND ND ND 2 1 1 1 ST2
IDRL-11125 Cervix 0.25 2 0.125 0.125 1 1  ND ND ND ND 2 14e 1 1 ST110f
IDRL-11207 Vagina 1 4 0.125 0.125 1 0.5  ND ND ND ND 1 2 1 1 ST22
IDRL-11257 TA 0.5 2 0.125 0.125 0.25 0.25  ND ND ND ND 1 1 1 1 ST1
IDRL-11271 Cervix 0.5 2 0.125 0.125 2 2  ND ND ND ND 2 1 1 1 ST2
U. urealyticum
IDRL-10763 BAL 4 16 0.25 0.125 2 2  WT WT S83L WT 5 3 4 5 ST7
IDRL-11217 Urine 4 16 0.25 0.125 2 2  WT WT WT WT 5 3 4 4 ST47
IDRL-10967 Vagina 2 8 0.5 0.125 2 2  WT WT WT WT 5 3 4 4 ST47
IDRL-11184 Vagina 2 8 0.5 0.125 2 2  WT WT WT WT 5 3 4 4 ST47
IDRL-11235 TA 0.5 4 0.25 0.125 2 2  ND ND ND ND 42e 3 4 18e ST112f
IDRL-11135 Urine 1 4 0.5 0.125 2 2  ND ND ND ND 6 3 4 11 ST54
IDRL-10787 Cervix 2 8 0.25 0.125 1 1  ND ND ND ND 5 3 4 4 ST47
IDRL-10928 Urine 0.5 2 0.25 0.125 0.25 0.25  ND ND ND ND 4 11 4 4 ST113f
IDRL-11163 Cervix 0.5 4 0.125 0.125 1 1  ND ND ND ND 4 3 4 4 ST9
IDRL-11213 Vagina 0.5 4 0.25 0.125 2 2  ND ND ND ND 41 3 4 11 ST101
IDRL-11269 Cervix 0.5 2 0.5 0.125 2 2  ND ND ND ND 6 3 4 11 ST54
IDRL-11295 Urine 0.5 2 0.125 0.125 1 1  ND ND ND ND 42e 3 4 18e ST112f
IDRL-11298 Urine 0.5 2 0.125 0.125 2 1  ND ND ND ND 5 3 4 4 ST47
IDRL-11299 Urine 0.5 2 0.125 0.125 1 0.5  ND ND ND ND 4 3 4 4 ST9
IDRL-11306 Urine 0.5 2 0.125 0.125 1 0.5  ND ND ND ND 5 3 4 5 ST7
IDRL-11308 Urine 2 8 0.25 0.125 1 0.5  ND ND ND ND 4 3 4 4 ST9
a BAL, bronchoalveolar lavage fluid; TA, tracheal aspirate.
b LEV, levofloxacin; CIP, ciprofloxacin; TET, tetracycline; DOX, doxycycline; ERY, erythromycin; AZM, azithromycin.
c WT, wild type; ND, not done.
d ST, sequence type.
e New alleles; numbering starts from the last alleles reported by Zhang et al. (17) and Schneider et al. (9).
f New STs; numbering starts from the last profiles reported by Zhang et al. (17) and Schneider et al. (9).
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found with ST47 (five isolates) and ST9 (three isolates), which
belong to the same CC, being themost common. Five and six new
alleles and ST profiles, respectively, were discovered. Detailed re-
sults are shown in Table 2. The eBURST package revealed three
main clusters (I to III) and a single nongroupable clone (two iso-
lates). Cluster I comprised the totality ofU. parvum isolates, while
most of U. urealyticum isolates were distributed in clusters II and
III (Fig. 1). No correlation between ST and antimicrobial resis-
tance was observed (Table 2).
DISCUSSION
Ureaplasma species have been recognized as important pathogens
in recent years, not only for their potential pathogenicity linked to
urogenital tract or intrauterine infections but also for their ability
to produce systemic diseases in newborns and immunosup-
pressed patients (1–4, 6, 18). The limited therapeutic options
available to combat infections by these microorganisms make it
important to understand their susceptibility to potentially active
antimicrobials such as the fluoroquinolones, tetracyclines, and
macrolides. There are few data available on antimicrobial suscep-
tibility of Ureaplasma, especially in terms of individual species.
Prior data have been produced using the Mycoplasma IST2 kit
(bioMérieux, Marcy l’Étoile, France), which has been shown to
compare poorly with the reference broth microdilution method
(9, 12). Also, inconsistencies can occur due to the use of varying
interpretative criteria (9, 12). One of the reasons for the limited
data available about Ureaplasma susceptibility relates to difficul-
ties in cultivation and in the performance of broth microdilution
(especially in regard to preparation of the inoculum). Although
CLSI guidelines recommend testing each drug in duplicate, we
suggest that this may be not necessary. Of the six antimicrobials
tested against the 250 isolates (a total of 1,500 tests), only nine
differences in the MICs between duplicates were found, and they
were never greater than the single dilution variability inherent to
any broth microdilution method. By eliminating the testing of
duplicates, costs could be reduced, and the protocol could be sim-
plified; this method would thus be rendered more applicable for
use in clinical microbiology laboratories.
The fluoroquinolone resistance rate inUreaplasma species var-
ies widely among different countries and studies. For instance, in
a recent study carried out in Switzerland, Schneider et al. reported
a rate of nonsusceptibility to ciprofloxacin of 19.4% (9), while in a
recent study in Italy, 41% of isolates were ciprofloxacin resistant
(19). Levofloxacin was not tested in these studies. However, in
another study carried out using clinicalUreaplasma isolates recov-
ered fromneonates in England andWales between 2007 and 2013,
a much lower ciprofloxacin resistance rate of 1.5% was reported,
with no levofloxacin resistance found. Regarding the United
States, very limited data have become available regarding the fre-
quency of fluoroquinolone resistance inUreaplasma species since
the first description of a resistant strain in 2006 (13). Before our
work, a single studywas carried out to evaluate the occurrence and
molecular mechanisms of fluoroquinolone resistance in clinical
Ureaplasma isolates from the United States and reported a levo-
floxacin resistance rate of 5% (ciprofloxacin was not tested) (20).
These results are similar to those from our study in which we
found levofloxacin resistance rates of 6.4% and 5.2% inU. parvum
and U. urealyticum, respectively. Interestingly, although there
was no overall difference in the percentages of resistance be-
tween the species, fluoroquinolone MIC50 and MIC90 values
were one dilution higher for U. urealyticum than for U. parvum.
Furthermore, the percentage of isolates with ciprofloxacin MICs
of 4 g/ml was higher for U. urealyticum (68.8%) than for U.
parvum (27.2%).
Sequence analysis of the QRDRs in levofloxacin-resistant iso-
lates revealed that the mechanism of resistance was due to muta-
FIG 1 Population distribution of 46Ureaplasma isolates established with eBURST. Three clusters (cluster I, consisting ofU. parvum isolates; clusters II and III,
consisting ofU. urealyticum isolates) and the remaining single clone are indicated. The number of isolates is shown for those sequence types with more than one
isolate.
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tions in parC, with a Ser83Leu substitution being most frequent,
followed by a Glu87Lys substitution (Table 2). Both substitutions
have been previously reported, with the first being the most fre-
quent mutation responsible for fluoroquinolone resistance in
Ureaplasma species worldwide (9–12, 21). A single levofloxacin-
resistantU. urealyticum isolate and the three levofloxacin-suscep-
tible isolates with high ciprofloxacin MICs analyzed did not
harbor QRDR mutations. An absence of QRDR mutations in
fluoroquinolone-resistant isolates has been previously reported,
suggesting that undescribed resistance mechanisms may exist in
these isolates (9).
It is interesting that no macrolide resistance was found among
theUreaplasma isolates studied; this is consistent with the low rate
of resistance to this antimicrobial group previously reported in
several countries, including the United States (9, 12, 22).
A single doxycycline-resistant isolate (U. parvum) was found
although 4.9% of the isolates of this species were positive for the
tet(M) gene. These data contrast with the 33% tetracycline resis-
tance rate previously reported in the United States in Ureaplasma
species (22). The presence of tet(M) in tetracycline-susceptible
isolates had been previously documented (11, 12, 23). Some
tet(M) variants may exhibit inducible resistance, and therefore it
may be necessary to screen by both broth microdilution to assess
phenotypic susceptibility andmolecular methods to detect tet(M)
variants (12).
MLST showed a high diversity within the clinical Ureaplasma
isolates studied, regardless of antimicrobial susceptibility. Isolates
were grouped in three clusters and demonstrated high correlation
between the groups and species for U. parvum (cluster I) and U.
urealyticum (clusters II and III), as previously observed in stud-
ies from China and Switzerland (9, 17). Most of the clones
found in this study were described in Chinese and Swiss pop-
ulations; furthermore, some (ST1, ST2, ST4, ST9, ST47, ST54,
and ST101) were associated with fluoroquinolone resistance in
Switzerland (9). Since the Ureaplasma MLST scheme has been
developed only recently, further studies are necessary to ex-
pand the knowledge about clonality in this species. Together
with the information provided by the previous two studies, our
results suggest that, as in other species, some clonal lineages of
Ureaplasma species could have increased epidemic potential
that may be associated with pathogenicity or spread of antimi-
crobial resistance.
In conclusion, the present work extends previous knowledge
regarding susceptibility to antimicrobial agents, resistance mech-
anisms, and clonality in Ureaplasma species in the United States,
knowledge which could contribute to optimized treatment of in-
fections caused by these pathogens and better understanding of
their epidemiology.
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